The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis
Abstract
Objective: Vision loss and cerebrovascular accidents often complicate giant cell arteritis (GCA). Antiplatelet and anticoagulant therapy reduce the risk of stroke in other populations. We sought to determine whether antiplatelet or anticoagulant therapy reduces ischemic complications in patients with GCA. Methods: A retrospective chart review for patients with GCA was conducted. Included patients fulfilled modified 1990 American College of Rheumatology criteria for GCA. Collected information included demographic data, dates of antiplatelet or anticoagulant use, vision loss or stroke, and presence of bleeding complications and cerebrovascular risk factors. Results: A total of 143 patients were included with a mean followup period of 4 years. The cohort included 109 women (76%) and 34 men (24%) with a mean age of 71.8 years. A total of 104 patients (73%) had a biopsy‐proven diagnosis. Eighty‐six patients (60.1%) had received long‐term antiplatelet or anticoagulant therapy, including 18 (12.6%) who did not start therapy until after an ischemic event had occurred. Antiplatelet agents or anticoagulants were not used in 57 patients (39.9%). Overall, 11 of 68 patients (16.2%) had an ischemic event while receiving antiplatelet or anticoagulant therapy, compared with 36 of 75 patients (48.0%) not receiving such therapy (P < 0.0005). Univariate analysis failed to show a statistical difference between groups in regard to cerebrovascular risk factors, age, sex, or biopsy‐proven diagnosis. Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy. Conclusion: Antiplatelet or anticoagulant therapy may reduce the risk of ischemic events in patients with GCA. An increased risk of bleeding complications was not observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
Hunder, G. G., Bloch, D. A., Michel, B. A., Stevens, M. B., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., Lie, J. T., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330810 · Cited by 2,539
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke
Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011258 · Cited by 1,168
The way I see it: House officers need formal career development
Connor, A. (2002) · BMJ · doi:10.1136/bmj.324.7336.s71 · Cited by 1,143
Hoffman, G. S., Cid, M. C., Hellmann, D. B., Guillevin, L., Stone, J. H., Schousboe, J., Cohen, P., Calabrese, L. H., Dickler, H., Merkel, P. A., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10262 · Cited by 579
Self-citationLow‐dose aspirin and prevention of cranial ischemic complications in giant cell arteritis
Nesher, G., Berkun, Y., Mates, M., Baras, M., Rubinow, A., & Sonnenblick, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20171 · Cited by 429
González-Gay, M. A., Blanco, R., Rodríguez-Valverde, V., Martínez-Taboada, V. M., Delgado-Rodriguez, M., Figueroa, M., & Uriarte, E. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199808)41:8<1497::aid-art22>3.0.co;2-z · Cited by 408
Salvarani, C., Cimino, L., Macchioni, P., Consonni, D., Cantini, F., Bajocchi, G., Pipitone, N., Catanoso, M. G., & Boiardi, L. (2005) · Arthritis Care & Research · doi:10.1002/art.21075 · Cited by 284
Salvarani, C., Crowson, C. S., O'Fallon, W. M., Hunder, G. G., & Gabriel, S. E. (2004) · Arthritis Care & Research · doi:10.1002/art.20227 · Cited by 282
Weisman, S. M., & Graham, D. Y. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.19.2197 · Cited by 279
Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy
Hayreh, S. S., & Zimmerman, B. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00228-8 · Cited by 200
Therapeutic effects of acetylsalicylic acid in giant cell arteritis
Weyand, C. M., Kaiser, M., Yang, H., Younge, B. R., & Goronzy, J. J. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10071 · Cited by 155
The epidemiology of giant cell arteritis
Liu, N. H., LABREE, L. D., Feldon, S. E., & Rao, N. A. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00574-7 · Cited by 119
Costello, F., Zimmerman, M. B., Podhajsky, P. A., & Hayreh, S. S. (2004) · European Journal of Ophthalmology · doi:10.1177/112067210401400310 · Cited by 92
Cited by
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., de Boysson, H., Brouwer, E., Cassie, R., Cid, M. C., Dasgupta, B., Dejaco, C., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215672 · Cited by 1,200
Polymyalgia rheumatica and giant-cell arteritis
Salvarani, C., Cantini, F., & Hunder, G. G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61077-6 · Cited by 767
Polymyalgia Rheumatica and Giant Cell Arteritis
Ettlinger, R. E., Hunder, G. G., & Ward, L. E. (1978) · Annual Review of Medicine · doi:10.1146/annurev.me.29.020178.000311 · Cited by 687
Giant Cell Arteritis and Polymyalgia Rheumatica
Stone, J. R., Pless, M., Salvarani, C., Pipitone, N., Lessell, S., & Stone, J. H. (2009) · A Clinician's Pearls and Myths in Rheumatology · doi:10.1007/978-1-84800-934-9_27 · Cited by 308
Giant cell arteritis: A review of classification, pathophysiology, geoepidemiology and treatment
Borchers, A. T., & Gershwin, M. E. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.01.003 · Cited by 256
Metadata
- Authors
- Lee, M. S., Smith, S. D., Galor, A., & Hoffman, G. S.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-09-28
- Volume
- 54
- Issue
- 10
- Pages
- 3306-3309
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1968590536
- Cited by
- 304
- References
- 15
- FWCI
- 16.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.